Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mouse Model
100%
Tumor Immunity
100%
Melanoma
100%
Therapeutic Response
100%
Recombinant interleukin-2
100%
Low-dose interleukin-2
100%
Tumor Growth
25%
Tumor
25%
High Dose
16%
CD8+
16%
CD4+ T
8%
Placebo
8%
Immunogenic
8%
Therapeutic Efficacy
8%
Treg
8%
Natural Killer Cells
8%
Day 14
8%
C57BL
8%
Metastatic Melanoma
8%
Melanoma Cells
8%
Renal Cell Carcinoma
8%
Clinical Activity
8%
Objective Response
8%
Placebo Treatment
8%
Patient Cohort
8%
Antitumor Therapeutics
8%
Gp100
8%
CD4+ Regulatory T Cells
8%
B16F10 Melanoma
8%
Immunotherapy Agent
8%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Neoplasm
100%
Melanoma
100%
Interleukin 2
100%
Recombinant Interleukin 2
100%
Low Drug Dose
100%
Tumor Growth
25%
Placebo
16%
Clinical Study
16%
CD8 Antigen
16%
Adjuvant
8%
Immunotherapy
8%
Renal Cell Carcinoma
8%
C57BL 6 Mouse
8%
Metastatic Melanoma
8%
Glycoprotein Gp 100
8%
Immunology and Microbiology
Mouse Model
100%
Tumor Immunity
100%
Low Drug Dose
100%
Interleukin 2
100%
Recombinant Interleukin 2
100%
Regulatory T Cell
16%
Drug Megadose
16%
Adjuvant
8%
CD4
8%
T-Helper Cell
8%
Immunotherapy
8%
Cytotoxic T-Cell
8%
Natural Killer Cell
8%
C57BL 6 Mouse
8%
CD8
8%
Biochemistry, Genetics and Molecular Biology
Mouse Model
100%
Low Drug Dose
100%
Interleukin 2
100%
Tumor Immunity
100%
Tumor Progression
23%
CD4
15%
Drug Megadose
15%
Clinical Study
15%
Regulatory T Cell
15%
CD8
15%
T Cell
7%
Natural Killer Cell
7%
C57BL 6 Mouse
7%